market-access
(8)
Amy Mahery Learned the Business by Moving Toward the Hard Parts
Her career began with a rugby conversation in an airport lounge. Two decades later, the Moderna marketing chief still treats curiosity, range and access to information as operating tools.
AcuityMD
AcuityMD is a Boston-based commercial intelligence platform built specifically for the medical device (MedTech) industry. It translates large volumes of healthcare claims and procedure data into intuitive workflows, AI-powered insights, and recommendations that help medical device sales and marketing teams find high-value physicians and care sites, size and segment markets, manage territories, and accelerate product adoption. Founded in 2019 by former MedTech and consulting operators, the company serves hundreds of device makers - including a majority of the largest MedTech firms - and raised an $80M Series C in 2026 at a near-$1B valuation.
Courier Health
Courier Health is a New York City software company building the first patient relationship management (CRM) platform purpose-built for life sciences. Its AI-powered system connects fragmented data across biopharma commercial teams to orchestrate the patient journey - from education and enrollment through benefits, prior authorization, therapy initiation, and adherence - helping patients with chronic and rare diseases start and stay on treatment. The company raised a $50M Series B led by Oak HC/FT in April 2026.
Lyfegen
Lyfegen is a Swiss health-tech company that builds software to manage value-based drug pricing and rebate agreements. Its platform helps health insurers, governments, hospital payers, pharmaceutical firms and medical device makers automate complex rebate contracts, run pricing simulations and tap the world's largest library of value-based agreements - reducing administrative burden while helping patients access innovative therapies.
Girisha Fernando
Girisha Fernando is the CEO and co-founder of Lyfegen, a Basel- and Boston-based healthtech company building software that helps payers, hospitals, pharma companies and medical device makers manage value-based drug pricing, access and rebate agreements. After nearly a decade at Roche in market access, pricing and IT, he left in 2018 to build technology that ties the price of medicine to how well it actually works for patients. He splits his time between Switzerland and New York as Lyfegen pushes into the US market.
Claritas Rx
Claritas Rx is a South San Francisco-based health-tech company that turns fragmented specialty pharmacy, channel, and clinical data into actionable intelligence for biopharmaceutical manufacturers. Its AI-powered Ascend platform integrates disparate patient-level data sources so drug makers can see how their specialty and rare-disease products perform, identify access barriers, and coordinate patient support - helping more patients start and stay on therapy.
Mohan Purushothaman
Mohan Purushothaman is the co-founder, chairman, and CEO of Progentec Diagnostics, an Oklahoma City company building blood tests and digital tools that aim to predict autoimmune disease flares before they happen. He came to diagnostics by an unusual route: a Johns Hopkins Ph.D. focused on pharmaceutical pricing, a Harvard research fellowship, five years inside Roche, and a pricing-software practice he built and sold to Alliance Life Sciences. In 2014 he turned that commercial instinct toward lupus, partnering with the Oklahoma Medical Research Foundation, and in 2020 raised a $5M Series A led by Plains Venture Partners to bring the aiSLE DX flare-prediction platform and the LupusCorner patient community to market.
Mike Fitzgibbons
Mike Fitzgibbons is the CEO and Founder of Claritas Rx, a South San Francisco-based healthtech company that uses AI and real-world patient-level data to help biopharmaceutical companies track, understand, and support patients across the specialty drug treatment journey. Founded in 2011, Claritas Rx serves 20+ rare and specialty therapeutic areas and has appeared on Inc.'s 2025 list of America's Fastest-Growing Private Companies. Before founding Claritas Rx, Fitzgibbons spent seven years at Morgan Stanley as an equity research analyst covering pharma services and drug distribution, then joined Genentech where he worked on pricing strategy and led the Avastin marketing team - experiences that directly shaped his conviction that patient-level data, not aggregated reports, is what biopharma companies actually need.